Biocon shares were in focus on Thursday, November 13, rising over 3% to trade near ₹420 after the company posted a strong set of numbers for the September quarter (Q2 FY26). The gains also came after fresh positive commentary from global brokerage HSBC.
The biopharma major reported a nearly 20% year-on-year jump in consolidated revenue to ₹4,296 crore, driven by strong traction in its biosimilars business across the US, Europe and emerging markets. Operating profit (EBITDA) rose over 40% YoY, supported by higher volumes and cost efficiencies.
Management said the quarter reflected the resilience of Biocon’s diversified model, with Chairperson Kiran Mazumdar-Shaw highlighting continued investment in R&D and innovation-led growth. The generics and research-services verticals also posted steady expansion.
What brokerages are saying
HSBC on Biocon
-
Rating: Buy
-
Target Price: ₹455 per share
-
Key view: Biocon has settled structured debt obligations with Goldman Sachs and Kotak using QIP funds and expects to settle dues with Edelweiss by Jan 2026.
-
HSBC believes interest cost relief will free up cash flows, enabling sharper focus on the high-growth biosimilars segment.
-
The brokerage expects market share gains from recent biosimilar launches to remain a key earnings driver.
Bottom line
The stock has reacted positively to Biocon’s strong Q2 performance and supportive brokerage commentary. However, investors should evaluate risks, competition in biosimilars, and financial leverage before taking any call.
Disclaimer:
Brokerage views mentioned are solely those of the respective firms and do not represent the views of the author or Business Upturn. This article is for informational purposes only and should not be considered investment advice.
